Table 4.
Subgroup analyses for validation of performance of RMI, CA125, GOT-1 (RMI + HE4), and GOT-2 (CA125 + HE4) comparing benign disease with EOC in dualistic model Type I and Type II tumors.
| Group (n) | Model | Type I | Type II | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ROC | SN% (75% SP) | SP% (Target SN) | ROC | SN% (75% SP) | SP% (Target SN) | ||||
| AUC | 95% CI | AUC | 95% CI | ||||||
| Benign (445) vs. Type I (36)/Type II (99) | RMI (cut-off <200) | 0.89 | 0.84–0.94 | 94 | 84 | 0.97 | 0.95–0.98 | 98 | 84 |
| GOT-1 (RMI + HE4) | 0.90 | 0.84–0.95 | 94 | 85 | 0.97 | 0.95–0.99 | 97 | 89 | |
| Benign (445) vs. Type I (36)/Type II (99) | CA125 (cut-off >35 U/mL) | 0.85 | 0.79–0.91 | 75 | 68 | 0.94 | 0.91–0.97 | 93 | 68 |
| GOT-2 (CA125 + HE4) | 0.87 | 0.82–0.93 | 83 | 80 | 0.96 | 0.94–0.99 | 96 | 71 | |
Specificity was calculated using target SN. Target SN = target sensitivity of RMI at cut-off >200 was 83% (type I) and 95% (type II); target sensitivity of CA125 at cut-off >35 was 83% (type I) and 96% (type II). AUC = area under the curve; EOC = epithelial ovarian cancer; GOT-1 = Gothenburg index 1; GOT-2 = Gothenburg index 2; Pre-M = premenopausal; Post-M = postmenopausal; ROC = receiver operating characteristics; SN = sensitivity; SP = specificity; Type I = low-grade tumors; Type II = high-grade tumors.